ATHA Athira Pharma Inc
Price (delayed)
$0.27
Market cap
$10.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.52
Enterprise value
-$37.31M
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive
Highlights
The company's debt fell by 23% YoY and by 7% QoQ
The EPS is up by 18% YoY and by 12% QoQ
ATHA's quick ratio is up by 42% from the previous quarter but it is down by 23% YoY
ATHA's equity has plunged by 66% YoY and by 22% from the previous quarter
Key stats
What are the main financial stats of ATHA
Market
Valuations
Earnings
Shares outstanding
39.04M
Market cap
$10.54M
Enterprise value
-$37.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.23
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$100.9M
Net income
-$96.94M
EBIT
-$96.94M
EBITDA
-$95.73M
Free cash flow
-$97.2M
Per share
Balance sheet
Liquidity
EPS
-$2.52
EPS diluted
-$2.52
Free cash flow per share
-$2.53
Book value per share
$1.16
Revenue per share
$0
TBVPS
$1.53
Total assets
$58.78M
Total liabilities
$13.94M
Debt
$1.22M
Equity
$44.84M
Working capital
$41.71M
Debt to equity
0.03
Current ratio
4.18
Quick ratio
3.95
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-99.5%
Return on equity
-132.6%
Return on invested capital
-2,613.8%
Return on capital employed
-212.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATHA stock price
How has the Athira Pharma stock price performed over time
Intraday
-5.23%
1 week
-19.48%
1 month
-34.26%
1 year
-89.24%
YTD
-53.98%
QTD
-5.23%
Financial performance
How have Athira Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$100.9M
Net income
-$96.94M
Gross margin
N/A
Net margin
N/A
ATHA's operating income is up by 20% YoY and by 12% from the previous quarter
ATHA's net income is up by 18% year-on-year and by 11% since the previous quarter
Growth
What is Athira Pharma's growth rate over time
Valuation
What is Athira Pharma stock price valuation
P/E
N/A
P/B
0.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% YoY and by 12% QoQ
ATHA's P/B is 77% below its 5-year quarterly average of 1.1 and 69% below its last 4 quarters average of 0.8
ATHA's equity has plunged by 66% YoY and by 22% from the previous quarter
Efficiency
How efficient is Athira Pharma business performance
ATHA's return on equity has dropped by 92% year-on-year and by 15% since the previous quarter
Athira Pharma's ROA has plunged by 66% YoY and by 12% from the previous quarter
Dividends
What is ATHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATHA.
Financial health
How did Athira Pharma financials performed over time
The total assets has dropped by 63% year-on-year and by 32% since the previous quarter
ATHA's total liabilities has dropped by 54% year-on-year and by 51% since the previous quarter
The company's debt is 97% lower than its equity
The company's debt to equity has surged by 200% YoY and by 50% QoQ
ATHA's equity has plunged by 66% YoY and by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.